Table 7 Relative risk and 95% confidence interval of UGIB associated with anticoagulants according to daily dose as well as the interaction with NSAIDs.
| Cases (n = 2777) | Controls (n = 5532) | Age‐adjusted RR (95% CI) | Adjusted condition RR (95% CI)* | |
|---|---|---|---|---|
| Anticoagulants | ||||
| Non‐use | 2598 | 5327 | Reference | Reference |
| Dicumarinics 1 mg | 55 | 73 | 1.6 (1.1 to 2.2) | 2.6 (1.6 to 4.0) |
| Dicumarinics 2–3 mg | 47 | 70 | 1.4 (1.0 to 2.0) | 2.4 (1.5 to 3.8) |
| Dicumarinics ⩾4 mg | 33 | 19 | 3.6 (2.0 to 6.4) | 6.6 (3.2 to 13.4) |
| Dicumarinics dose unknown | 44 | 43 | 2.1 (1.4 to 3.3) | 2.8 (1.7 to 4.8) |
| Anticoagulants and NSAIDs† | ||||
| Non‐use | 1784 | 4500 | Reference | Reference |
| NSAID use only | 622 | 504 | 3.0 (2.6 to 3.4) | 5.0 (4.2 to 5.9) |
| Dicumarinics only | 144 | 196 | 1.8 (1.5 to 2.3) | 2.8 (2.1 to 3.7) |
| Combination | 35 | 9 | 9.7 (4.6 to 20.2) | 19.3 (8.2 to 45.3) |
NSAIDs, non‐steroidal anti‐inflammatory drugs; UGIB, upper gastrointestinal bleeding.
*Adjusted for age, sex, calendar semester, ulcer history, nitrates, antiplatelets, acid‐suppressing drugs, coxib and aspirin use.
†Categorised only among NSAID current single users.